FDA Approves Mirum's Atebrioz for FOP, First Drug to Reduce New Bone Growth
MIRM sits 44% above its 52-week low of $63.232.
Summary
The FDA approved Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), a devastating ultra-rare disease affecting ~300 U.S. patients. This is the first therapy shown to reduce new heterotopic ossification volume—the hallmark of FOP—with a 3.2 cm3 decrease vs a 24.6 cm3 increase on placebo at 24 weeks. Mirum licensed the drug from Incyte and will commercialize it in the U.S. starting October 2026, with a patient support program offering $0 copay for eligible patients. Incyte received a Rare Pediatric Disease Priority Review Voucher, a valuable asset. The approval validates Mirum's rare disease strategy and adds a second commercial product to its portfolio, following LIVMARLI. An EMA decision is pending, and pediatric cohorts are enrolling to expand the label to younger children.
At the time of this announcement, MIRM was trading at $91.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.